19.86

1.49% -0.30

Pre-market: 19.96 0.10 +0.50%

Apellis Pharmaceuticals Inc (APLS)

Overview News Price History Option Chain Financials Why APLS Down? Discussions Forecast

Apellis Pharmaceuticals Inc stock is traded at $19.86, with a volume of 2.87M. It is down -1.49% in the last 24 hours and down -14.21% over the past month. Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).

Previous Close:

$20.16

Open:

$20.32

24h Volume:

2.87M

Relative Volume:

1.05

Market Cap:

$2.54B

Revenue:

$715.22M

Net Income/Loss:

$-250.10M

P/E Ratio:

-9.7833

EPS:

-2.03

Net Cash Flow:

$-205.58M

1W Performance:

-7.28%

1M Performance:

-14.21%

6M Performance:

-30.68%

1Y Performance:

-20.72%

1-Day Range:

$19.55

$20.32

1-Week Range:

$19.55

$22.12

52-Week Range:

$16.10

$30.48

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name

Apellis Pharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

617-977-5700

Address

100 FIFTH AVENUE, WALTHAM, KY

Employee

733

Twitter

@ApellisPharma

Next Earnings Date

2024-12-05

Latest SEC Filings

APLS's Discussions on Twitter

Compare APLS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APLS Apellis Pharmaceuticals Inc	19.86	2.58B	715.22M	-250.10M	-205.58M	-2.03
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Initiated	Barclays	Equal Weight
Jan-21-26	Upgrade	BofA Securities	Neutral → Buy
Nov-06-25	Initiated	Wolfe Research	Peer Perform
Oct-15-25	Initiated	Wells Fargo	Overweight
Sep-26-25	Downgrade	Goldman	Neutral → Sell
May-09-25	Downgrade	BofA Securities	Buy → Neutral
May-09-25	Downgrade	Raymond James	Strong Buy → Outperform
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Dec-17-24	Downgrade	Goldman	Buy → Neutral
Nov-21-24	Initiated	Morgan Stanley	Equal-Weight
Oct-25-24	Initiated	RBC Capital Mkts	Sector Perform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-16-24	Initiated	William Blair	Outperform
May-31-24	Initiated	Piper Sandler	Neutral
Feb-05-24	Upgrade	Jefferies	Hold → Buy
Dec-14-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-09-23	Initiated	Goldman	Buy
Nov-02-23	Initiated	Mizuho	Neutral
Oct-06-23	Upgrade	JP Morgan	Neutral → Overweight
Sep-15-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Aug-29-23	Reiterated	Citigroup	Buy
Aug-03-23	Downgrade	JP Morgan	Overweight → Neutral
Aug-01-23	Downgrade	BofA Securities	Buy → Neutral
Jan-03-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-10-22	Downgrade	Jefferies	Buy → Hold
Jul-19-22	Initiated	H.C. Wainwright	Buy
Jun-17-22	Resumed	Stifel	Buy
Apr-14-22	Downgrade	ROTH Capital	Neutral → Sell
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-29-21	Downgrade	ROTH Capital	Buy → Neutral
Sep-10-21	Reiterated	BMO Capital Markets	Outperform
Sep-10-21	Reiterated	Credit Suisse	Neutral
Sep-10-21	Reiterated	Needham	Buy
Sep-10-21	Reiterated	Oppenheimer	Outperform
Sep-10-21	Downgrade	Wedbush	Outperform → Neutral
Aug-19-21	Initiated	Jefferies	Buy
Aug-19-21	Upgrade	Wedbush	Neutral → Outperform
May-21-21	Initiated	UBS	Buy
Apr-16-21	Initiated	Goldman	Buy
Nov-19-20	Initiated	Needham	Buy
Sep-01-20	Initiated	Stifel	Buy
Jul-20-20	Initiated	ROTH Capital	Buy
Jun-17-20	Initiated	BTIG Research	Neutral
Apr-01-20	Initiated	Raymond James	Strong Buy
Mar-31-20	Initiated	BMO Capital Markets	Outperform
Mar-11-20	Upgrade	Wedbush	Underperform → Neutral
Jan-07-20	Initiated	SVB Leerink	Mkt Perform
Dec-19-19	Initiated	BofA/Merrill	Buy
Nov-22-19	Initiated	Wedbush	Underperform
Nov-05-19	Initiated	Credit Suisse	Neutral
Aug-01-19	Reiterated	Cantor Fitzgerald	Overweight
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Mar-29-19	Initiated	Robert W. Baird	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Jul-30-18	Upgrade	B. Riley FBR	Neutral → Buy
May-24-18	Initiated	Cantor Fitzgerald	Overweight
Apr-12-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Feb-08-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Apellis Pharmaceuticals Inc Stock (APLS) Latest News

Mar 04, 2026

Update Recap: Will Apellis Pharmaceuticals Inc benefit from geopolitical trendsMarket Performance Summary & Daily Technical Forecast Reports - baoquankhu1.vn

Mar 04, 2026

Mar 03, 2026

Apellis Pharmaceuticals (APLS) director receives new stock options and RSUs - Stock Titan

Mar 03, 2026

Apellis (APLS) director Mikael Dolsten submits initial Form 3 insider filing - Stock Titan

Mar 03, 2026

Apellis Pharmaceuticals (APLS) Stock Analysis: Exploring a 62.73% Upside Potential in Biotech - DirectorsTalk Interviews

Mar 03, 2026

Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf. - MarketBeat

Mar 03, 2026

Mar 02, 2026

Apellis adds former Pfizer research chief to board - Investing.com

Mar 02, 2026

Apellis Pharmaceuticals2026 Funding Rounds & List of Investors - Tracxn

Mar 02, 2026